Contineum Therapeutics, Inc. (CTNM)
| Market Cap | 478.54M +50.4% |
| Revenue (ttm) | n/a |
| Net Income | -57.56M |
| EPS | -1.72 |
| Shares Out | 37.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 508,398 |
| Open | 13.14 |
| Previous Close | 13.12 |
| Day's Range | 12.41 - 13.30 |
| 52-Week Range | 8.60 - 17.79 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 22.43 (+76.34%) |
| Est. Earnings | Oct 29, 2026 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price target is $22.43, which is an increase of 76.34% from the latest price.
News
Jones sees greater room for Contineum’s PIPE-791 to differentiate
Jones reiterated a Buy rating and $24 price target on Contineum (CTNM) after a competitor report identified a Phase 3 long-term extension protocol amendment that newly classifies liver injury as…
Contineum Therapeutics Inc trading resumes
16:00 EDT Contineum (CTNM) Therapeutics Inc trading resumes
Contineum Therapeutics Inc trading halted, volatility trading pause
15:50 EDT Contineum (CTNM) Therapeutics Inc trading halted, volatility trading pause
Contineum price target lowered to $17 from $18 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Contineum (CTNM) to $17 from $18 and keeps an Equal Weight rating on the shares. Following the MOONLIGHT-1 study…
Contineum resumed at Early-Stage Biotech at Goldman Sachs
Goldman Sachs resumed coverage of Contineum (CTNM) with an Early-Stage Biotech rating. Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite a back...
Contineum Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-origin innovation and AI are driving efficiency and new BD opportunities. PIPE-791, a once-daily LPA1R antagonist for IPF, is differentiated by its lack of dose titration and strong receptor occupancy. The company is funded through mid-2029, focusing on PROPEL-IPF while monitoring the evolving competitive landscape.
Contineum price target lowered to $24 from $26 at Jones
Jones lowered the firm’s price target on Contineum (CTNM) to $24 from $26 and keeps a Buy rating on the shares. PIPE-307 was well-tolerated but didn’t hit the primary endpoint…
Contineum price target lowered to $19 from $20 at Baird
Baird lowered the firm’s price target on Contineum (CTNM) to $19 from $20 and keeps an Outperform rating on the shares. The fim updated its model its announcement its PIPE-307…
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.
Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint
The company states: “Contineum (CTNM) Therapeutics announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-A...
Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint
16:09 EDT Contineum (CTNM) down 11% atter MOONLIGHT-1 trial did not achieve endpoint
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Contineum (CTNM) with an Outperform rating and $24 price target
Contineum reports Q2 EPS (40c), consensus (45c)
Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026. Contineum (CTNM) believes its cash resources are sufficient to fund its planned operations through mid-2029. “...
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum Therapeutics Earnings release: Q2 2026
Contineum Therapeutics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Contineum Therapeutics Quarterly report: Q2 2026
Contineum Therapeutics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry
Contineum (CTNM) Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, “Discovery of PIPE...
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key focus is on advancing PIPE-791 in IPF, with phase II enrollment progressing and strong differentiation from competitors due to dosing convenience and safety. Additional programs in pain and MDD are advancing, supported by a robust financial position and strategic partnerships.
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
PIPE-791 demonstrated promising pain reduction and strong safety in early studies, with greater efficacy in osteoarthritis. The focus remains on IPF, where the drug may offer advantages in dosing, safety, and quality of life. The company is well-funded and progressing with robust clinical trials.
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Contineum price target raised to $16 from $14 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Contineum (CTNM) to $16 from $14 and keeps an Equal Weight rating on the shares.